Actinogen Medical Limited
ACW.ASXHealth Care
Development and commercialisation of new therapeutic compounds
Market Data
$0.041
-0.0%$152.4M
-100000.0x
$-0.006
0.00%
-0.1%
Latest Earnings
Actinogen HY2025 financial report and Appendix 4D
26 February 2026
Actinogen Medical reported a HY2025 net loss of $11.3M, a 39% increase from $8.2M in the prior corresponding period, primarily driven by increased R&D spending of $8.9M. Key highlight was completing enrollment of 247 participants in the pivotal XanaMIA Alzheimer's trial and receiving a positive interim safety and efficacy recommendation from the Data Monitoring Committee. The company received $7.4M in R&D tax incentives and secured an additional $4.3M non-dilutive funding post-period. Key points: Completed enrollment of 247 participants in pivotal XanaMIA phase 2b/3 AD trial (exceeded target of 220); Received positive interim safety and efficacy futility analysis recommendation from independent Data Monitoring Committee; Achieved common understanding with FDA on pathway to marketing approval including streamlined design of one additional pivotal trial
Recent Announcements
Becoming a substantial holder
Dr Steven Gourlay became a substantial holder (5.47%).
Actinogen HY2025 financial report and Appendix 4D
Actinogen Medical reported a HY2025 net loss of $11.3M, a 39% increase from $8.2M in the prior corresponding period, primarily driven by increased R&D spending of $8.9M. Key highlight was completing enrollment of 247 participants in the pivotal XanaMIA Alzheimer's trial and receiving a positive interim safety and efficacy recommendation from the Data Monitoring Committee. The company received $7.4M in R&D tax incentives and secured an additional $4.3M non-dilutive funding post-period. Key points: Completed enrollment of 247 participants in pivotal XanaMIA phase 2b/3 AD trial (exceeded target of 220); Received positive interim safety and efficacy futility analysis recommendation from independent Data Monitoring Committee; Achieved common understanding with FDA on pathway to marketing approval including streamlined design of one additional pivotal trial
Get real-time alerts for ACW
Receive AI-powered earnings summaries and instant notifications when Actinogen Medical Limited releases results.
Register Free